Netherlands - Re-Imbursed Pharmaceutical Market
Since 2014, Netherlands Re-Imbursed Pharmaceutical Market was up 3.6points year on year. At 19.7 Percent of Generics in Value in 2019, the country was number 13 comparing other countries in Re-Imbursed Pharmaceutical Market. Netherlands is overtaken by Switzerland, which was number 12 with 20.4 Percent of Generics in Value and is followed by Ireland at 15.5 Percent of Generics in Value. Austria ranked the highest with 52.2 Percent of Generics in Value in 2019, a growth of 2.8points compared to 2018. United Kingdom, Turkey and New Zealand respectively ranked number 2, 3 and 4 in this ranking. Denmark recorded the best 5 years average growth at +6.9points per year, while Slovakia recorded the worst performance at -7.8points per year.
Loading...
Date | Percent of Generics in Value |
---|---|
2019 | 19.70 |
2018 | 20.00 |
2017 | 17.90 |
2016 | 16.80 |
2015 | 16.50 |
How does Netherlands rank in Re-Imbursed Pharmaceutical Market?
# | 17 Countries | Percent of Generics in Value | Last | YoY | 5‑years CAGR | ||
---|---|---|---|---|---|---|---|
1 |
#1
Austria
|
52.20 % | 2019 | +2.8 % | +2.2 % | View data | |
2 |
#2
United Kingdom
|
38.50 % | 2019 | +2.1 % | +2.6 % | View data | |
12 |
#12
Switzerland
|
20.40 % | 2019 | +1.5 % | +1.5 % | View data | |
13 |
#13
Netherlands
|
19.70 % | 2019 | -1.5 % | +3.6 % | View data | |
14 |
#14
Ireland
|
15.50 % | 2019 | +4.0 % | -1.1 % | View data |